LA ROCHE POSAY Anthelios UVMUNE 400 Hydrating Cream SPF50+ Sunscreen Face Cream with Hypoallergenic Fragrance, 50ml

A ROCHE POSAY Anthelios UVMUNE 400 Hydrating Cream SPF50+ Sunscreen Face Cream with hypoallergenic fragrance

VERY HIGH PROTECTION. VERY DURABLE. INVISIBLE.

ANTHELIOS UVMUNE 400 HYDRATING CREAM SPF50+: With MEXORYL400, the most effective sunscreen filter against the most harmful UV rays: ULTRA LONG UVA*. Absolute protection (UVB + UVA + ULTRA LONG UVA) against deep cellular damage. Tested on sensitive, reactive and intolerant skin. Suitable for all skin types, all phototypes.

Extremely resistant: to water and sand. Optimal tolerance. It doesn’t sting the eyes. Invisible, moisturizing texture. With hypoallergenic fragrance.

APPLICATION: For daily use and exposure to the sun Apply sunscreen just before exposure. Apply regularly and generously to maintain the level of protection, especially after sweating or toweling off.

TEXTURE: Invisible finish. Non greasy. Non-sticky. With La Roche-Posay Thermal Water.

KEY BENEFITS:

For sensitive or reactive skin. Also suitable for sun-allergic skin.

Can be applied around the eyes. It doesn’t sting the eyes. Hypoallergenic.

For more than 25 years, Anthelios has been a pioneer in important innovations: UVA filters, broad-spectrum protection, textures and technologies. For all skin types, all phototypes.

THE SCIENCE BEHIND THE PRODUCT:

XL-PROTECT:A patented filter technology provides very high broad-spectrum UVB/UVA protection and helps protect against damage caused by pollution and infrared radiation.

MEXORYL400: a new exclusive UV filter that protects even from the most harmful UV rays: ULTRA LONG UVA * up to 400nm.

With NETLOCK TECHNOLOGY for Absolute protection, extremely resistant to an invisible texture.

Dermatologically tested on sensitive and reactive skin.

Ophthalmologically tested on sensitive eyes and eye contour. Tested on contact lens wearers.

Allergy tested.

La Roche-Posay sun care is recommended by 60,000 dermatologists worldwide*

*Source: Dermocosmetic market research conducted by AplusA and other partners during the period January 2021-July 2021, including dermatologists in 34 countries, representing over 82% of global GDP

Expiry date after opening the package: 12 months

BASIC INGREDIENTS

MEXORYL: The revolution in sun protection for 30 years: new exclusive sun filter that protects even from the most harmful UV rays: ultra long UVA*.

* [380-400νμ] = Long UVA/ [380-400nm] = end of the spectrum we call ultra long UVA.

NETLOCK TECHNOLOGY: Very high protection in an invisible texture. With a non-greasy and non-sticky composition. The micro-crystals are grouped together creating a strong coverage network that protects it from running providing a homogeneous, very durable protection.

GLYCERIN: Glycerin deeply moisturizes the skin from the first application.

Ingredients: AQUA / WATER / EAU ● DIISOPROPYL SEBACATE ● ALCOHOL DENAT. ● ETHYLHEXYL SALICYLATE ● ETHYLHEXYL TRIAZONE ● BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE ● DIISOPROPYL ADIPATE ● PEG-8 ● DIPROPYLENE GLYCOL ● C12-22 ALKYL ACRYLATE/HYDROXYETHYLACRYLATE COPOLYMER ● GLYCERIN ● DROMETRIZOLE TRISILOXANE ● ALUMINUM STARCH OCTENYLSUCCINATE ● BUTYL METHOXYDIBENZOYLMETHANE ● METHOXYPROPYLAMINO CYCLOHEXENYLIDENE ETHOXYETHYLCYANOACETATE ● SILICA ● TOCOPHEROL ● DIETHYLAMINO HYDROXYBENZOYL HEXYL BENZOATE ● ACRYLATES COPOLYMER ● ACRYLATES/C10-30 ALKYL ACRYLATE CROSSPOLYMER ● CAPRYLYL GLYCOL ● HYDROXYACETOPHENONE ● PENTAERYTHRITYL TETRA-DI-T-BUTYL HYDROXYHYDROCINNAMATE ● SODIUM POLYACRYLATE ● TEREPHTHALYLIDENE DICAMPHOR SULFONIC ACID ● TRIETHANOLAMINE ● TRISODIUM ETHYLENEDIAMINE DISUCCINATE ● PARFUM / FRAGRANCE ● N283516/1

ITS PROVEN IMMEDIATE AND LASTING EFFECTIVENESS

90 % Clinically proven effectiveness through clinical studies, tested under dermatological and ophthalmological control.

Visible results confirmed by consumers*:

94.6% skin feels comfortable

99.1% skin feels hydrated

For 93.6% the product is absorbed quickly

For 98.2% the product does not leave white marks on the skin after application.**

*Clinical study on 113 people, immediately after use.

**Clinical study on 113 people, 14 days after use.